PF-Atlas › Clinical Trials › NCT02067182

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

Dabigatran · Phase 4

Registry ID

NCT02067182

Phase

Phase 4

Status

Completed

Drug / intervention

Dabigatran

Sponsor

Georg Nickenig

Start

2015-08

About this trial

Dabigatran is evaluated in NCT02067182, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Georg Nickenig. Current status: Completed.

View NCT02067182 on ClinicalTrials.gov →

Explore related

All Dabigatran trials All IPF trials

Related trials

Dabigatran — NCT02885961

Medical disclaimer. This page summarizes public trial data for NCT02067182 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.